Single-cell transcriptomics reveals the prognostic and immune infiltration significance of FOLFOX-bevacizumab treatment and lysine crotonylation characteristics in colon cancer. (PubMed, J Gastrointest Oncol) - Jul 12, 2026 - "Colon cancer (CC), a malignant tumor originating from the colonic mucosal epithelium, frequently exhibits limited efficacy in advanced patients undergoing first-line FOLFOX (oxaliplatin, leucovorin, and 5-fluorouracil)-bevacizumab (FOLFOX-Bev) therapy due to resistance...Six categories of differential candidate drugs were screened (e.g., Erlotinib_1168, AZD3759_1915, Dasatinib_1079, and Sepantronium.bromide_1941)...The prognostic model, based on key genes (USP53/UACA/C7orf50/IDH2), accurately stratifies patient risk. This model provides novel insights for targeted therapy and immune-combination strategies in CC."
IO biomarker • Journal • Colon Adenocarcinoma • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Solid Tumor • IDH2
|
|
Jinping Chen; Shiyang Zhan; Shurong Huang; Wei Zheng; YangQiang Wang; Zongda Cai
|